INTRODUCTION
Alzheimer disease (AD) is a neurodegenerative disease and the primary cause of dementia (Giannakopoulos et al., 2003) . The robust synaptic and neuronal loss in the hippocampal and cortical areas of the brain is accompanied by the accumulation of misfolded proteins, such as the amyloid b peptide (Ab), and by neurofibrillary tangles in affected sites in the parenchyma and vasculature of the brain (Iqbal et al., 2016; Orr et al., 2017; Selkoe and Hardy, 2016) . Together, these changes appear to be neurotoxic and cause chronic innate inflammation (Andreasson et al., 2016; Heneka et al., 2015; Van Eldik et al., 2016; Wyss-Coray and Rogers, 2012; Zotova et al., 2010) . Innate inflammation in the brain is characterized primarily as a glial activation process, in which both astrocytes and microglia accumulate around amyloid plaques and, thereby, exhibit activated and dysfunctional phenotypes that further increase neurotoxicity (Block et al., 2007; Serrano-Pozo et al., 2011) . Whether adaptive immunity mediated by CD4 T cells plays a key role in the inflammatory process in the brain and can be therapeutically used to abrogate the disease is still a matter of debate.
CD4 T cells play a key role in immune regulation and can substantially impact neuroinflammatory processes in the central nervous system (CNS), such as those observed in multiple sclerosis (Hoppmann et al., 2015; Peeters et al., 2017) , amyotrophic lateral sclerosis (Chiu et al., 2008) , and Parkinson disease (Mosley and Gendelman, 2017; Sulzer et al., 2017) . The infiltration of CD4 T cells into the brain can be destructive (Anderson et al., 2014; Walsh et al., 2014) , but, depending on the neuroinflammatory process and the phenotypes of these T cells, they can also limit neuronal damage caused by infection (Russo and McGavern, 2015) , stroke (Liesz et al., 2009) , or neurodegenerative diseases (Bryson and Lynch, 2016) . Studies in people with AD Parachikova et al., 2007; Togo et al., 2002; Zota et al., 2009) and in mouse models of the disease (Baek et al., 2016; Baruch et al., 2015 Baruch et al., , 2016 Dansokho et al., 2016) suggest that certain CD4 lymphocyte subsets can markedly impact the disease process. We previously showed that whereas peripheral Ab immunization can cause meningoencephalitis (Monsonego et al., 2006) , intracerebroventricularly (ICV)-injected T helper 1 (Th1) T cells can target Ab plaques in the brain parenchyma and, thereby, locally impact the neuroinflammatory niche to enhance Ab clearance and reduce innate inflammation, with no evidence of neurotoxic inflammation (Fisher et al., 2014) . Notably, these effects of the T cells were mostly brain antigen specific and were not observed to the same extent with ICV-injected ovalbumin (OVA)-specific Th1 T cells (Fisher et al., 2014) . Overall, these studies demonstrate that peripheral CD4 T cells can migrate into the brain and locally exert effector functions, which impact the progression of AD, possibly due to local interactions with major histocompatibility complex class II (MHCII)-expressing cells.
The expression of MHCII in the brain is low under homeostatic conditions, whereas it can be upregulated in microglia following brain infection or trauma, or over the course of neurodegenerative diseases (McGeer et al., 1987; Schetters et al., 2017; Streit et al., 1999) . In people with AD, MHCII expression was found to be upregulated by microglia at sites of Ab plaques (McGeer et al., 1987; Parachikova et al., 2007) . Studies in mice have shown that microglia can differentiate to functional antigen-presenting cells (APCs) (Ebner et al., 2013; Gottfried-Blackmore et al., 2009; Wlodarczyk et al., 2015) , and two recent single-cell RNA sequencing studies have shown subsets of microglia that appear in the course of neurodegeneration and potentially function as APCs (Keren-Shaul et al., 2017; Mathys et al., 2017) . Although MHCII-expressing microglia emerge during neurodegeneration, their functional role as T-cellstimulating APCs over the course of AD is as yet unclear.
Here, to determine the role of brain APCs in promoting the effector functions of T cells within the brain parenchyma, we ICV-injected Ab-specific T cells to 5XFAD mice that lack MHCII-expressing cells, either entirely or only in the brain.
RESULTS

ICV Injection of Ab-specific Th1 Cells to 5XFAD Mice Decreases Ab Plaques, Which Is Associated with Increased Expression of MHCII by Parenchymal APCs
Using the APP/PS1 mouse model of AD, we have previously demonstrated that whereas T cell activation, but not antigen specificity, was required for ICV-injected T cells to migrate into the brain parenchyma, the induction of MHCII+ cells was more pronounced with Ab-than with OVA-specific T cells (Fisher et al., 2014) . We thus first examined whether ICV-injected Ab-specific T helper 1 (Ab-Th1) cells induce the expression of MHCII in the brain of the 5XFAD mouse model of AD. To this end, we generated GFP-expressing Ab-Th1 cells by immunizing 2-month-old C57BL6 wild-type (WT) mice with Ab1-42, followed by in vitro expansion, polarization, and a GFP-encoding retrovirus transduction of Ab-Th1 cells ( Figure S1 and Transparent Methods). Next, the GFP+ Ab-Th1 cells underwent anti-CD3/anti-CD28 dynabeads activation and was ICV-injected ( Figure 1A ) to 9-month-old WT female mice (Th1/WT) or to 5XFAD female mice (Th1/ AD), which accumulate amyloid plaques in the brain by age 2 months . As control groups, age-and sex-matched WT and 5XFAD mice were ICV-injected with PBS (PBS/AD). Mice were killed at 11 or 21 days post-injection (dpi) and their brains were excised and analyzed with immunohistochemistry (IHC) and real-time quantitative PCR (qPCR). We found that the ICV-injected GFP+ T cells migrated into the brain parenchyma and that a portion of the cells accumulated at the vicinity of Ab plaques (11 dpi, Figure 1B ). Similar to our results in a previous study (Fisher et al., 2014) , the amyloid burden in the brain of 9-month-old 5XFAD mice killed at 21 dpi was significantly reduced in the cortex of Th1/AD mice, when compared with PBS/AD mice ( Figure 1C ). Figure S1A ). 5XFAD mice were ICV-injected with either Ab-Th1 T cells or PBS, killed at 11 or 21 days post-injection (dpi), and their brains collected and analyzed by IHC or qPCR. (A) Illustration of a representative coronal view of the adult mouse brain and the injection site in the lateral ventricle. (B) A representative IHC image (left) of Ab plaques co-localized with GFP+ T cells (green) in brain sections derived from 5XFAD mice 11 dpi of activated Ab-Th1 cells. Sections were immunolabeled with anti-Ab (red) and a DAPI nucleus counterstain (blue). The middle image is a higher magnification of the framed area, showing the interaction between Ab and Ab-Th1 T cells. The right image is a 3D reconstruction of z-sections (9.75 mm overall, 0.75 mm/slice) of the framed area. Scale bars, 200 mm (left), 50 mm (middle), and 5 mm (right). (C) Representative IHC images showing Ab plaque load in brain sections derived from 5XFAD mice ICV-injected with either PBS (PBS/AD, left) or Ab-Th1 T cells (Th1/AD, right). Sections were taken at 21 dpi (n = 4-5 mice per group) and immunolabeled with anti-Ab plaques (red) and a DAPI nucleus counterstain (blue). Scale bars, 200 mm. The quantitative analysis of the Ab plaque load in the cortex (right graph) was performed with IMARIS and shows the mean G SEM results of one experiment out of four performed. (D) Representative IHC images showing the upregulation of MHCII+ cells in brain sections derived from either PBS/AD (left) or Th1/AD (right) mice at 21 dpi (n = 6 mice per group), immunolabeled with anti-MHCII (green), anti-Ab (red), and a DAPI nucleus counterstain (blue). The higher magnifications of the framed areas reveal MHCII+ cells accumulating near the Ab plaques. Scale bars, 200 mm in the low-magnification images and 50 mm in the high-magnification images. The quantitative analysis of the number of MHCII+ cells per volume of cortical section (right graph) was performed with IMARIS. Each symbol represents an individual mouse, whereas the horizontal lines indicate the mean G SEM of one experiment out of four performed. (E) qPCR analysis of CD74 expression in the cortex (left) and hippocampus (right) of Th1/AD and PBS/AD mice at 21 dpi (n = 6-7 mice per group). Bars represent means G SEM. (F) Representative IHC images demonstrating an immunological synapse between MHCII+ cells and GFP+ T cells in brain sections derived from Th1/AD mice at 11 dpi (n = 5 mice) and immunolabeled with anti-phalloidin (cytoskeletal marker, blue), anti-MHCII (red), and GFP T cells (top images), or with anti-Zap70 (phospho Tyr 319) (red), anti-MHCII (blue), GFP T cells, and a DAPI nucleus counterstain (gray) (bottom images). In the top images, the middle and right panels are 3D reconstructions of z-sections (11.25 mm overall, 0.75 mm/slice). Scale bars, 10 mm. In the bottom images, the middle and right images are a 3D reconstruction of z-sections (7 mm overall, 0.5 mm/slice), which was then sliced in the xy axis. The front orientation of the xy-sliced 3D reconstruction shows an immunological synapse via Zap70 (phospho Tyr 319) (right). Scale bars, 10 mm (left) and 5 mm (middle and right images). *p < 0.05, **p < 0.01, ***p < 0.001 ((C and D) Student's t test and (E) one-way ANOVA). soma size and thickened processes, which represent their activation state or their dysfunctional properties (Andreasson et al., 2016; Davies et al., 2017; Spittau, 2017; Walker and Lue, 2015) . To test whether the MHCII+ cells are morphologically distinct from MHCIIÀ cells and impact the phagocytic capacity of Ab in the brain, we prepared sagittal brain sections from Th1/AD mice. The sections were immunolabeled for Iba1, MHCII, and Ab, and the proportion of Ab localized to MHCII+ cells was analyzed with the IMARIS software. A co-labeling IHC analysis revealed that MHCII+ cells primarily colocalize with IbaI+ and Ab at the vicinity of plaque (Figure 2A ). To determine whether the MHCII+ cells phagocytose Ab, the 3D reconstructed images were sliced in the xy plane using a clipping tool in IMARIS. The unsliced panels ( Figure 2B ; left, upper, and lower panels) show the interactions of MHCII+ and MHCIIÀ cells with Ab, whereas the xy-sliced panels ( Figure 2B ; right, upper, and lower panels) demonstrate Ab engulfed by the cells. A quantitative analysis demonstrated that the MHCII+ cells co-localized with Ab more efficiently than with MHCIIÀ cells (Figure 2B ), thus presumably indicating an upregulation of phagocytic activity.
To morphologically characterize MHCII+ and MHCIIÀ cells, confocal z stacks were captured and the images were manually traced by the backbone of the cells, using the IMARIS Filament Tracer plug-in. The tree area, total branch length, and number of bifurcations were calculated with IMARIS. We found that, whereas MHCIIÀ microglia show the typical ramified morphology, the MHCII+ cells that surround the plaques exhibit a more amoeboid-like morphology with an enlarged soma size ( Figure 2C) . A manual 3D reconstruction of MHCIIÀ and MHCII+ cells is shown in Figure 2C . Quantitative analyses of the reconstructed images show that MHCII+ Iba1+ cells exhibit a decrease in the spatial coverage area (Figure 2D ), process length ( Figure 2E ), and process bifurcation ( Figure 2F ), when compared with MHCIIÀ Iba1+ cells. This finding suggests that the MHCII+ Iba1+ subset of cells, which expands in 5XFAD mice upon an ICV injection of Ab-specific Th1 cells, may represent a beneficial response in the brain by reducing plaque burden.
MHCII-Knockout 5XFAD Mice Exhibit an Exacerbated Amyloid Pathology
MHCII expression by myeloid cells is essential for the selection and activation of CD4 T cells, a process that may facilitate the overall uptake of Ab in the brain. Therefore, we backcrossed 5XFAD mice onto MHCII-knockout (KO) background mice to generate 5XFAD mice that lack MHCII (5XFAD/MHCII À/À mice). Age-matched littermates were used as WT and 5XFAD control groups ( Figures 3A and S2 ). Then we characterized the inflammatory reaction in the brain and the accumulation of Ab plaques in 5XFAD/ MHCII À/À and 5XFAD mice at 1, 3, and 6 months age. Brain sections were first immunolabeled with antiAb, and the volume occupied by Ab plaques in the cortex was calculated using IMARIS. Surprisingly, and despite the use of an aggressive model of amyloidosis, we found that Ab accumulated in the brain by 1 month age in 5XFAD/MHCII
, whereas almost no plaques were observed in 5XFAD mice ( Figure 3B ). Furthermore, at older ages, the volume of Ab plaques in 5XFAD/MHCII À/À mice was nearly 2-fold higher than in 5XFAD mice ( Figure 3B ). To determine whether gene expression indicating inflammatory reaction in the brain was similarly upregulated in 5XFAD and 5XFAD/MHCII À/À mice, we used qPCR. A significant upregulation of mRNAs encoding interleukin (IL)-1b and glial fibrillary acidic protein (GFAP) was found in 5XFAD and in 5XFAD/MHCII À/À mice, when compared with littermate control mice, both at 3 and 6 months of age ( Figure 3C ). The mRNA levels of IL-6 and interferon (IFN)-g were not upregulated in either 5XFAD or 5XFAD/MHCII À/À mice at 3 months of age, whereas they were significantly upregulated in 5XFAD/MHCII À/À mice at 6 months of age, when compared with either 5XFAD or littermate control mice ( Figure 3C ).
To determine whether the increase in plaque pathology observed in 5XFAD/MHCII À/À mice was due to a reduced clearance of Ab in the brain, we used high-resolution confocal microscopy and 3D image reconstruction. Brain sections from 6-month-old 5XFAD/MHCII À/À and 5XFAD mice were immunolabeled for Ab and Iba1 and the proportion of Ab engulfed by activated microglia was analyzed. Notably, the 3D reconstruction of the IHC image showed that whereas Iba1+ cells penetrated the plaques in 5XFAD mice, they were primarily in the plaque vicinity in 5XFAD/MHCII À/À mice ( Figure 3D ). Furthermore, the 3D reconstructed image was sliced in the xy axis using IMARIS, demonstrating Ab engulfed by the Iba1+ cells. A quantitative analysis of the fraction of Ab co-localized with microglia was significantly lower in brain sections of 5XFAD/MHCII À/À (0.26% G 0.06%) than in those of 5XFAD mice (0.54% G 0.06%) ( Figure 3D ).
Immunolabeling for Ab, Iba1, and the lysosome marker CD68 revealed a marked decrease in Iba1+ CD68+ cells co-localized with Ab plaques in the brain of 5XFAD/MHCII À/À mice ( Figure S3 ). In addition, the qPCR analysis demonstrated a decrease in the mRNA levels of the phagocytic markers TREM-2 and SIRP-1b in the brain of 5XFAD/MHCII
, when compared with those in the brain of 5XFAD mice, which was significant for both genes at 6 months of age, and only for SIRP-1b at 3 months of age ( Figure 3E ). Taken together, these results indicate that, in the absence of MHCII, the phagocytic capacity of microglia in the brain is reduced; this is accompanied by a dysregulation of the inflammatory reaction in the brain and an exacerbated Ab pathology.
ICV-Injected Ab-Th1 Cells Exhibit Reduced Effector Functions in 5XFAD/MHCII À/À Mice
To determine whether the exacerbated pathology observed in 5XFAD/MHCII À/À mice can be recovered by using activated CD4 T cells, we subjected Ab-Th1 cells to polyclonal activation with anti-CD3/anti-CD28 dynabeads and ICV-injected them to 7-month-old 5XFAD/MHCII À/À mice and to 5XFAD mice. Mice were killed at 21 dpi, a time required to determine T cell effector functions induced by brain APCs, and their brains were analyzed for the presence of CD4 T cells, Ab plaque load, and inflammatory mediators. Surprisingly, IHC analysis of the cortex revealed that although the CD4 T cells migrated into the brain of 5XFAD/MHCII À/À , no differences in plaque load were observed, when compared with mice ICV-injected with PBS ( Figures 4A and 4B ). Furthermore, the qPCR analysis showed that the mRNAs encoding the Th1 cytokine IFN-g and the chemokines CXCL9, CXCL10, and CXCL11, which are ligands of the CXCR3 receptor on Th1 T cells, were only slightly upregulated in 5XFAD/MHCII À/À mice ICV-injected with Th1 cells, when compared with 5XFAD mice ICV-injected with Th1 cells ( Figure 4C ). In light of these observations, we sought to determine whether the reduced clearance of Ab in 5XFAD/MHCII À/À mice ICV-injected with Ab-Th1 cells is due to a reduced monocyte infiltration into the brain. To test this hypothesis, brain cells were isolated enzymatically from all the groups of mice at 21 dpi and analyzed with flow cytometry. Single cells were gated for CD45+ CD11b+ myeloid cells, which were then analyzed for putative infiltrating CX3CR1ÀLy6C+ macrophages ( Figure 4D ). CX3CR1ÀLy6C+ cells were indeed observed in the brain of 5XFAD mice that had been ICV-injected with Ab-Th1 cells; however, this phenomenon was observed neither in 5XFAD/MHCII À/À mice ICV-injected with Ab-Th1 cells nor in the respective PBS-injected control groups ( Figures 4E and S4 ).
Taken together, these results indicate that MHCII expression by microglia or infiltrating macrophages results in the stimulation of T cells, which consequently impacts the inflammatory milieu and Ab accumulation. Methods). Of the 12 mice that received BM transplants, six were injected with Ab-Th1 cells 8 weeks after the BM transplantation. Then, at 28 dpi, the mice were killed and perfused and their brains were excised and analyzed using both IHC and flow cytometry. As expected, the IHC analysis revealed enhanced infiltration of GFP+ BM-derived cells in BMC mice that were ICV-injected with Ab-Th1 cells, when compared with untreated BM-transplanted mice ( Figure 5A) ; however, the accumulation of the infiltrating GFP+ BM-derived cells around A b plaques remained similar in both groups ( Figure 5B ). Next, we determined the Ab pathology of BMC mice that were either ICV-injected or not injected with Ab-Th1 cells and compared it with the pathology of untreated 5XFAD/MHCII À/À mice. An IHC analysis of the amyloid burden in the cortex of BMC mice revealed that, when compared with untreated 5XFAD/MHCII À/À mice, the plaque volume was significantly reduced ( Figure 5C ). Regardless of the enhanced infiltration of GFP+ BM-derived cells into the brains of 5XFAD/MHCII À/À mice ICV-injected with Ab-Th1 cells ( Figure 5A ), no further reduction in Ab was observed in these mice, when compared with the non-injected BMC mice ( Figure 5C ). Notably, the GFP+ macrophages infiltrating into the brain parenchyma were mostly detected as MHCIIÀ cells in BMC mice that were either ICV-injected or not injected with T cells ( Figure 5D ).
The results shown in Figure 5 suggest that the MHCII+ cells observed in 5XFAD mice ICV-injected with Ab-Th1 cells are primarily brain-endogenous microglia. To determine that microglia can indeed give rise to MHCII+ cells, 8-or 9-month-old 5XFAD mice were ICV-injected with Ab-Th1 cells and their brains were subjected to flow cytometry analysis at 21 dpi. Single cells were first gated for the CD45+ CD11b+ cells, and the gated cells were then plotted with the MHCII and Ly6C myeloid markers (Figures 6AÀ6C).
The fraction of MHCII+ cells out of the CD45+ CD11b+ cells was then analyzed for all groups (PBS/ littermates, PBS/ 5XFAD, and Th1/ 5XFAD), revealing a significant increase in MHCII+ cells in the brain parenchyma of mice ICV-injected with Ab-Th1 cells (9.79% G 1.29%), when compared with mice ICV-injected with PBS (3.95% G 0.39%) ( Figure 6B ). MHCII+ cells from each group were then plotted for the Ly6C marker, which revealed 28.16% G 0.77% and 63.56% G 5.13% cells within the presumed infiltrating CD45+ CD11b+ Ly6C high macrophages and brain-endogenous CD45+ CD11b+ Ly6C low microglia, respectively ( Figure 6C ). Next, we conducted an RNAscope fluorescence in situ hybridization at 14 dpi to identify the MHCII+ cells in the brains of 5XFAD mice ICV-injected with Ab-Th1 cells. P2ry12 and CD74 were used as markers of endogenous microglia (Butovsky et al., 2014; Zhu et al., 2017) and MHCII+ cells, respectively. Ppib (peptidyl-prolyl cis-trans isomerase B) was used as a positive control ( Figure 6D ). These analyses revealed that CD74 mRNA (yellow arrows) is expressed primarily in microglia cells expressing the P2ry12 mRNA (white arrows) ( Figure 6E ). Note that not all P2ry12-expressing microglia express CD74 and that, as expected, some cells are negative to both markers (pink arrow). Overall, these data suggest that the MHCII+ cells, which were observed in 5XFAD mice and with increased frequencies in 5XFAD mice ICV-injected with Ab-Th1 cells, are primarily endogenous microglia.
DISCUSSION
The aim of the current study was to test whether T cells can promote the differentiation of myeloid cells in the brain parenchyma into APCs with enhanced Ab uptake capacity. We demonstrate that Ab-Th1 cells, ICV-injected to 5XFAD mice, not only migrate into the brain parenchyma but also stimulate the expansion of MHCII+ cells. This process is associated with the activation of T cells, the modulation of the inflammatory reaction to Ab pathology, and enhancement of Ab uptake. We found that the newly differentiated MHCII+ cells originate primarily from brain-endogenous microglia. As such, this subset of MHCII+ microglia may serve to target therapeutic antigen-specific T cells directly to damaged sites within the CNS.
We have previously shown that Ab-specific T cells polarized to Th1 T cells and ICV-injected to APP/PS1 mice transmigrate into the brain parenchyma, where they impact the inflammatory response induced by Ab and enhance amyloid plaque uptake (Fisher et al., 2014) . However, it was unclear whether these T cells undergo reactivation by APCs within the brain parenchyma in a manner that stimulates their effector functions. Here, we found that MHCII+ cells expand in the brain parenchyma following an ICV injection of Ab-Th1 cells. Moreover, we show that these MHCII+ cells accumulate in the vicinity of Ab plaques and exhibit a less ramified morphology and enhanced phagocytic capacity, when compared with Iba+ microglia. Finally, we found that the MHCII+ cells interact with the injected T cells in a manner reminiscent of an immunological synapse, which is essential for T cell activation. Taken together, our findings suggest that, within the brain parenchyma, brain-infiltrating Ab-Th1 cells can stimulate the differentiation and expansion of MHCII+ cells, whose phagocytic and antigen presentation capacity is considerably greater than those of MHCIIÀ microglia.
Although MHCII in activated microglia is known to be upregulated at the vicinity of plaques in brains of people with AD (Hopperton et al., 2018; Parachikova et al., 2007; Schetters et al., 2017; Tooyama et al., 1990) and in mouse models of the disease (Landel et al., 2014; Mathys et al., 2017) , it remains unclear whether MHCII expression by microglia or infiltrating macrophages plays a role in the progression of AD. Surprisingly, we found that 5XFAD/MHCII À/À mice, which lack MHCII, exhibit a worsened amyloid pathology compared with 5XFAD mice, and that this pathology is accompanied by an enhanced innate inflammation. Furthermore, the Ab phagocytic capacity of microglia in 5XFAD/MHCII À/À mice was significantly reduced and the mRNA expression of SIRP-b1 and TREM2-two genes that play important roles in the activation and phagocytic machinery of microglia and macrophages in the brain (Finelli et al., 2015; Gaikwad et al., 2009; Hickman and El Khoury, 2014; Rivest, 2015; Zhang et al., 2015) -was downregulated. Notably, in contrast to SIRP-b1, TREM2 was significantly upregulated in 5XFAD mice (Keren-Shaul et al., 2017; Wang et al., 2015 Wang et al., , 2016 and was slightly downregulated in 5XFAD/MHCII À/À mice. These results suggest that CD4 T cell effector functions are required to effectively stimulate the phagocytic capacity of microglia within the brain, a mechanism that may involve not only the upregulation of phagocytic molecules but also the downregulation of inhibitory receptors such as LILRB1 (Barkal et al., 2018) . In line with these findings, a recent study demonstrated that Ab uptake is reduced in a Rag-5XFAD mouse model of AD, which lacks the entire cellular and humoral adaptive arms of the immune system, and that IgG treatment enhances the uptake of Ab in these mice (Marsh et al., 2016) . Overall, it is suggested that both humoral and cellular immune responses-orchestrated by CD4 T cells-play a significant role in the capacity of the brain to clear Ab.
Another important finding in this study was that, although we activated the Ab-Th1 cells before their ICV injection, they exhibited significantly reduced effector functions (as indicated by the reduced mRNA levels of IFN-g and CXCL9/10/11 chemokines and by the significantly reduced number of presumed infiltrating macrophages) in the brains of 5XFAD/MHCII À/À mice, when compared with 5XFAD mice. These findings suggest that the effector functions of the ICV-injected Ab-Th1 cells are facilitated by antigen presentation in the brain. It, however, remained unclear whether this T cell re-stimulation is mediated by brain-endogenous microglia or by peripheral macrophages. Generating a WT GFP/GFP / 5XFAD/MHCII À/À BMC mice, we recovered the leukocyte repertoire and turnover of the meningeal macrophages to MHCII+ cells, and thus, except for some infiltrating GFP+ cells, microglia in the brain of the BMC mice remained MHCIIÀ. Notably, whereas recovering the peripheral and meningeal leukocytes in the BMC mice reduced the amyloid load in the brain, the ICV-injected cells did not facilitate this reduction. These results strongly suggest that brain-endogenous MHCII+ microglia are required to re-stimulate the T cells. In line with our findings, a subset of MHCII+ microglia was recently observed in a mouse model of neurodegeneration and was suggested to be a type-II IFN-induced subset of microglia, which may potentially function as APCs (Mathys et al., 2017) . In addition, this subset is highly similar to disease-associated microglia, a subset that was recently reported in the 5XFAD mouse model of AD (Keren-Shaul et al., 2017) . More recently, a subset of MHCII+ microglia was observed within activated response microglia (ARMs) in a mouse model of AD (Sala Frigerio et al., 2019) . Interestingly, ARMs were more frequent in female than in male mice (Sala Frigerio et al., 2019), suggesting a gender variation in microglial phenotypes (Nelson et al., 2017; VanRyzin et al., 2019) , which may affect their activation profile in aging and disease. Taking together, a relatively low frequency of MHCII+ microglia accumulate in the brain during inflammation, a phenomenon that calls for further research to explore their origin, molecular characteristics, differentiation program, and functional properties.
Several studies previously reported a CD11c+ subset of microglia that accumulates in the CNS during neuroinflammation, and that is significantly different from CD11cÀ microglia (Kamphuis et al., 2016; Re et al., 2002; Wlodarczyk et al., 2015) . Thus it is possible that the higher levels of IFN-g found in the brain following the ICV injection of Ab-Th1 cells in our study further promote the expansion and differentiation of this subset to functional APCs. Indeed, using the RNAscope technique to co-label the mRNAs of the invariant chain CD74 and of the microglial marker P2ry12, we determined that the MHCII+ subset that accumulated at the plaque vicinity derives from brain-endogenous microglia. Our in vivo study thus strongly suggests that parenchymal microglia can function as APCs, and that this function is required to stimulate the ICV-injected T cells in 5XFAD mice.
Overall, our study suggests that the function of microglia as APCs plays an important role in brain immunity, which, based on the T cell phenotype (Th1, Th2, Th17, or regulatory T cells [Tregs] ), can exert either beneficial or neurotoxic responses. We have previously shown that the Th1 subset of cells is the most effective subset in preconditioning the brain for T cell migration, primarily due to IFN-g being the key cytokine that these T cells secrete (Fisher et al., 2014) . Hence, IFN-g appears to be required to promote the differentiation of certain subsets of microglia to APCs, which thereby acquire an enhanced phagocytic capacity (Fisher et al., 2014; Gottfried-Blackmore et al., 2009; , as well as to promote the various neuroprotective functions observed in animal models, such as in the induction of IL-6 expression in astrocytes during acute neuroinflammation (Sun et al., 2017) , the induction of IL-10 after spinal cord injury (Ishii et al., 2013) , and the induction of neurogenesis (Mastrangelo et al., 2009 ). The Th1 cells may be only the first arrivals into the brain, paving the way for regulatory T cells such as Th2/Tr1 or Foxp3+ Tregs, which were found to be important for immune regulation in mouse models of neurodegenerative diseases (Baruch et al., 2015; Kipnis et al., 2004; Mayo et al., 2016; Ochi et al., 2008; Perdigoto et al., 2015) . It cannot be excluded, though, that leukocytes such as CD8 T cells (Lassmann, 2018; Lassmann and Bradl, 2017) , natural killer cells, and neutrophils (Cruz Hernandez et al., 2019) may also infiltrate the brain and cause neurotoxicity. It is thus intriguing to examine whether the dysregulated CD4 T cells that are observed with aging (Harpaz et al., 2017; Moro-Garcia et al., 2013; Nikolich-Zugich, 2018) fail to properly regulate adaptive immunity in the brain and, therefore, facilitate neurotoxic inflammation and the progression of AD. This process of immune senescence may also explain why immunotherapies suitable for adults are not always effective for elderly individuals. Further characterizing immune senescence processes and their impact on neurotoxic inflammation may thus pave the way toward therapeutic approaches that target peripheral immune senescence, thus allowing a proper dialog between brain-infiltrating CD4 T cells and MHCII-expressing microglia, which may be required to promote neural repair in the AD brain.
Limitations of the Study
1. qPCR was used in the current study to analyze the expression of inflammatory genes in the brain. As some of these markers were not measured at the protein level, they represent transcriptional changes that do not necessarily define the proinflammatory phenotype of the cells.
2. Our experimental setup was based on ICV-rather than intravenous-injection of T cells, a process that may cause acute microglial activation and hence a relatively robust differentiation of microglial subsets to APCs. 
Supplemental
Transparent Methods Animals
Wild-type (WT) C57BL/6 mice (stock number 000664), 5XFAD transgenic (Tg) mice (Swedish K670N, M671L, Florida I716V, London V717I, and two mutations in the human presenilin-1 gene M146L and L286V; stock number 34848) , UBC-GFP mice (stock number 004353), and MHCII knockout (KO) mice (stock number 003584) (Madsen et al., 1999) were purchased from the Jackson Laboratory (Bar Harbor, ME). 5XFAD and MHCII KO mice were backcrossed to C57BL/6J mice for more than 10 generations. 
Confocal image analysis
Confocal images were generated with a 4-channel Olympus XI81-ZDC confocal microscope (Olympus, Hamburg, Germany) at a 1024 × 1024-pixel resolution with ×10, ×40, or ×60 objectives. To generate 3D images, a z-stack of at least 23 μm thickness, with serial images taken every 0.75 μm, was imaged in the confocal microscope.
3-D reconstruction of individual microglial cells
Z-stack confocal images of 20-40 μm in thickness, taken at intervals of 0.5 μm, were captured from layers 2 and 3 of the cortex (0 to 2 mm lateral to bregma). The images were reconstructed manually with the Filament Tracer plug-in in IMARIS. The backbones of the filaments were generated by selecting the nuclei of the individual microglia. The manual tracing of each process along the z-stack was achieved by selecting points along the midline of the microglial process taking the nucleus as a center, and then allowing the software to find the path and depth between them.
Calculation of morphometric parameters
The following morphometric parameters were calculated using the IMARIS software: 
Measurement of Aβ co-localization with microglia
Sections (35 mm thick) were imaged under a confocal microscope and 3D reconstructions were generated using the Surface plug-in in IMARIS. The 3D reconstructs were sliced by using a Clipping Plane plug-in in three different axes (XY, 
Aβ phagocytic analysis
Brain sections (35 mm-thick) were immunolabeled for Aβ (red), Iba1(green) and CD68
(blue) and images were taken at intervals of 0.5 μm from layers 2 and 3 of the cortex (0 to 2 mm lateral to bregma). 3D image reconstructions was generated using the Surface plug-in in IMARIS. For co-localization analysis, the 3D reconstructions were viewed in IMARISColoc, which operates on two channels simultaneously to measure the degree of overlap between the channels. The intensity threshold of the different channels was used according to the automatic threshold calculation option. The colocalization images were then saved as separated channels, which were processed using the 3D reconstruction plug-in, and the sum volume of co-localized Aβ out of total volume of Aβ was calculated. At least 3 mice per group (2-3 sections per brain hemisphere) were analyzed.
T-cell lines
Aβ-specific T cell line
Mice were immunized at 2 m of age by a footpad injection of Aβ1-42 (100 mg;
GenScript, Piscataway, NJ) emulsified in CFA H37Ra (Difco, Detroit, MI). The Aβ1-42 peptides used for immunization were initially dissolved in a small volume of DMSO to enhance solubility and then diluted to 2 mg/ml in PBS. The peptide was emulsified with CFA to a final concentration of 1 mg/ml. Ten days later, popliteal, inguinal, and iliac lymph nodes were extracted and the cells were seeded (5×10 6 cells/ml in 24-well culture dish) in an RPMI complete medium (Gibco) supplemented with 20 μg/ml of Aβ1-42. Every other day thereafter, human rIL-2 (20 U/ml) in complete DMEM was added to the solution. After one week and every two weeks later, the T cell cultures were re-stimulated with irradiated (6000 rad) splenocytes and re-seeded at 10 5 T cells/ml, 5 × 10 6 irradiated splenocytes/ml in 24-well plates .To generate Th1 cell subpopulations, we used anti-IL-4 (20 mg/ml, clone: 11B11; BioLegend, San Diego, CA) and mouse IL-12 (20 ng/ml; BioLegend). Recombinant cytokines and cytokineneutralizing antibodies were supplemented in the first three stimulations during seeding, and then 2 d later.
Retroviral Transduction of Th1 cells
The T2A-GFP peptide fusion was cloned into the retroviral vector pMP-71-G- 
Flow cytometry
Mice were sacrificed via isoflurane inhalation, quickly perfused, and their brains were collected in cold PBS. The mononuclear single-cell suspension was prepared according to standard protocols (Ferretti et al., 2016; Suter et al., 2003) The whole brain was minced and digested for 1 h at 37 °C in HBSS containing 50 µg/ml DNase I and 100 µg/ml collagenase/dispase (Roche, Rotkreuz, Switzerland). The suspension was passed through a 70-µm Nylon mesh (Falcon, BD Biosciences, Bedford, MA), pelleted, resuspended in 30% Percoll (GE Healthcare Bio-sciences, USA) in HBSS and centrifuged at 15,500 rpm for 30 min at 4 °C. After eliminating the myelin debris via aspiration, the mononuclear cell phase was collected. CNS-mononuclear cells were washed in a flow cytometry buffer (HBSS, 2% FCS, 10 mM EDTA). After treatment with an antibody against the Fc receptor (anti-mouse CD16/32, TrueStain FcX TM, BioLegend, San Diego, CA), the cells were stained for 15 min at 4 °C with specific antibodies, washed, and analyzed. A multicolor flow cytometry study was performed with a cytoflex.
Fluorescent in situ hybridization (FISH)
